Akari Therapeutics, Plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKTX research report →
About the company
Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes.
- CEO
- Abizer Gaslightwala
- IPO
- 2014
- Employees
- 8
- HQ
- London, FL, GB
Price Chart
- Market Cap
- $11.92M
- P/E
- -0.01
- P/S
- 0.00
- P/B
- 0.02
- EV/EBITDA
- -0.34
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -123.29%
- ROIC
- -130.49%
- Revenue
- $0 · 0.00%
- Net Income
- $-17,298,000 · 12.60%
- EPS
- $-20800.00 · 84.34%
- Op Income
- $-17,275,000
- FCF YoY
- 15.81%
- 52W High
- $49.60
- 52W Low
- $3.02
- 50D MA
- $9.82
- 200D MA
- $15.06
- Beta
- 1.33
- Avg Volume
- 800.64K
Get TickerSpark's AI analysis on AKTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 24, 26 | Farag Kameel D. | other | 1,000 |
| Jun 24, 26 | Farag Kameel D. | other | 7,353 |
| Jun 24, 26 | Farag Kameel D. | other | 3,725 |
| Jun 24, 26 | Farag Kameel D. | other | 2,539 |
| Jun 24, 26 | Farag Kameel D. | other | 1,570 |
| Jun 24, 26 | Farag Kameel D. | other | 1,395 |
| Jun 24, 26 | Farag Kameel D. | other | 1,248 |
| Jun 24, 26 | Gaslightwala Abizer | other | 15,563 |
| Jun 24, 26 | Gaslightwala Abizer | other | 5,500 |
| Dec 16, 25 | Neal James R | buy | 3,093 |
Our AKTX coverage
Recent articles, reports, and earnings notes.
No research on AKTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AKTX report →Similar companies
Peers in the same neighborhood.